Sugi Predict

Sugi Predict / Compounds / SCHEMBL375444

SCHEMBL375444

SCHEMBL375444

CC(C)(C)OC(=O)N1CCC(O[Si](C)(C)C(C)(C)C)C1CO

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.37
▸ NR1H2 P55055 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ TSHR P16473 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144302 1.00 ALDH1A1 (0.37) ALDH1A1NR1H2CHRM2CHRM1CHRM3
SCHEMBL24411299 1.00 ALDH1A1 (0.37) ALDH1A1NR1H2CHRM2CHRM1CHRM3
SCHEMBL142417 1.00 ALDH1A1 (0.37) ALDH1A1NR1H2CHRM2CHRM1CHRM3
SCHEMBL12979137 1.00 ALDH1A1 (0.37) ALDH1A1NR1H2CHRM2CHRM1CHRM3
SCHEMBL2960161 0.92 ALDH1A1 (0.43) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL13199602 0.92 ALDH1A1 (0.43) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL25765834 0.92 ALDH1A1 (0.43) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL29013071 0.92 ALDH1A1 (0.43) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL6052721 0.91 ALDH1A1 (0.35) ALDH1A1CHRM2CHRM1CHRM3TSHR
SCHEMBL5560106 0.91 ALDH1A1 (0.35) ALDH1A1CHRM2CHRM1CHRM3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2434889-B1 IAP INHIBITORS TETRALOGIC BIRINAPANT UK LTD (GB) 2016-03-09 — — EP disclosed
US-8841455-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors ARRAY BIOPHARMA INC. (US) 2014-09-23 — — US disclosed
EP-2516433-B1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS ARRAY BIOPHARMA INC (US) 2014-05-21 — — EP disclosed
EP-2049563-B1 DIMERIC IAP ANTAGONISTS TETRALOGIC PHARM CORP (US) 2014-03-12 — — EP disclosed
US-20130274278-A1 IAP INHIBITORS TETRALOGIC PHARM CORP (US) 2013-10-17 — — US disclosed
US-8481495-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2013-07-09 — — US disclosed
US-8415486-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-04-09 — — US disclosed
US-8399683-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS (US) 2013-03-19 — — US disclosed
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors ARRAY BIOPHARMA INC. (US) 2012-10-11 — — US disclosed
US-20120135990-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. (US) 2012-05-31 — — US disclosed
US-20110237517-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. 2011-09-29 — — US disclosed
US-7985735-B2 mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2011-07-26 — — US disclosed
EP-2328412-A1 IAP INHIBITORS Tetralogic Pharmaceuticals Corp. (US) 2011-06-08 — — EP disclosed
WO-2010138496-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. (US) 2010-12-02 — — WO disclosed
WO-2010138666-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. (US) 2010-12-02 — — WO disclosed
WO-2010033531-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP. (US) 2010-03-25 — — WO disclosed
US-20080020986-A1 DIMERIC IAP INHIBITORS TETRALOGIC BIRINAPANT UK LTD (GB) 2008-01-24 — — US disclosed
EP-1722793-A1 BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION Brystol-Myers Squibb Company (US) 2006-11-22 — — EP disclosed
WO-2005087232-A1 BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2005-09-22 — — WO disclosed
WO-1992002521-A1 1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-02-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080020986-A1 DIMERIC IAP INHIBITORS BIRC2, BIRC7, BIRC8 ALDH1A1 4403/4885NR1H2 4695/4885CHRM2 4860/4885
US-20110237517-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 ALDH1A1 4750/4885NR1H2 3860/4885CHRM2 4448/4885
US-20120135990-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 ALDH1A1 4750/4885NR1H2 3860/4885CHRM2 4448/4885
US-20130274278-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 ALDH1A1 4750/4885NR1H2 3860/4885CHRM2 4448/4885
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors AFF1, FLI1, F3 ALDH1A1 1771/4885NR1H2 3135/4885CHRM2 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.